A Phase 3 interventional study of Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel) and Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution) in Cataracts, sponsored by Alcon Research. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-26.
Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing moxifloxacin in Cataract — 1 open to participants now, 1 under way, 1 of them phase 3. Moxifloxacin · Cataract.
Among the 12 studies testing moxifloxacin in Cataract, this one is the 12th largest by enrollment, is the only one that started in 2014, is one of 2 in phase 3, and was the 7th registered.
1,632 studies on the registry are indexed under Cataract; 235 are open to participants now.
Browse Cataract studies →1 of the 12 studies testing moxifloxacin in Cataract is open now, in 1 country. Recruiting first, the newest first:
Laboratorios Sophia S.A de C.V. · Sites in Mexico
Ages 18+
By country, each count listing its studies:
Moxifloxacin: first FDA approval 1999 (AVELOX). What it is approved for, and how studies give it, is on its page →
Of the 142 Cataract studies recruiting now, 88 (62%) set no upper age limit and 8 (6%) stop at 75 or younger; 10 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 62 across the 12 interventional studies. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 12 have an industry lead sponsor. The 9 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
116 studies in Cataract by Alcon: 4 open now, 6 under way, none of them phase 3. Of 101 finished, 76 (75%) have results posted.
Among the 116 studies in Cataract by Alcon, this one is the 97th largest by enrollment of the 104 interventional ones that give a count, is one of 3 that started in 2014, is one of 14 in phase 3, and was the 58th registered.
Alcon’s Cataract studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing moxifloxacin in Cataract, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Alcon’s 116 in Cataract:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare VIGADEXA (moxifloxacin 0.5%/dexamethasone phosphate 0.075%) ophthalmic gel to VIGADEXA (moxifloxacin 0.5%/dexamethasone phosphate 0.1%) ophthalmic solution in the prevention of postoperative inflammation and infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VIGADEXA ophthalmic gel topically administered TID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.
Drug: Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)
VIGADEXA ophthalmic solution topically administered QID to the operative eye starting the day before surgery, continuing on the day of surgery, and for 15 days following surgery.
Drug: Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)
Drug page: Moxifloxacin
One ribbon (approximately 1-1.5 cm) administered topically in the conjunctival sac of the study eye three times daily (TID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
Also known as: FID 119149, VIGADEXA Gel
Drug page: Moxifloxacin
One drop administered topically in the conjunctival sac of the study eye four times daily (QID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
Also known as: VIGADEXA Solution
Percentage of patients with a score of 0 (<5 cells) for cells in the anterior chamber
As assessed by the investigator during slit-lamp examination.
Time frame: Day 15 post-operative
Percentage of patients with no clinically evidenced bacterial infection
As assessed by the investigator during slit-lamp examination.
Time frame: Day 15 post-operative
Cells in the anterior chamber (study eye)
As assessed by the investigator during slit-lamp examination.
Time frame: Day 15 post-operative
Ocular pain (study eye)
As assessed by the investigator during patient interview.
Time frame: Day 15 post-operative
Inflammatory reaction (study eye)
As assessed by the investigator during slit-lamp examination.
Time frame: Day 15 post-operative
No study locations are listed for this record.
The record gives a start of Mar 2014, a primary completion of Oct 2014 and a completion of Oct 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxifloxacin